GERON CORP (GERN)
About GERON CORP
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2023
- $237.0K
- Net income
- -$83.5M
- Total assets
- $570.5M
- Market cap
- $911.0M
- Operating margin
- -37.3%
- Net margin
- -45.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $183.9M
- Operating expenses
- $252.5M
- Operating income
- -$68.6M
- Income tax
- $75.0K
- Net income
- -$83.5M
- EPS (basic)
- $-0.13
- EPS (diluted)
- $-0.13
Balance sheet
- Total assets
- $570.5M
- Current assets
- $520.3M
- Total liabilities
- $344.7M
- Current liabilities
- $111.5M
- Shareholders’ equity
- $225.9M
Cash flow
- Operating cash flow
- -$111.0M
- Investing cash flow
- $107.2M
- Financing cash flow
- $2.3M
- Net cash flow
- -$1.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $911.0M
- EPS (diluted)
- $-0.13
- Shares outstanding
- 595.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 31, 1996
Geron Corp (GERN) Stock Price
- Reported a net loss of $83.5M in FY2023.
- Revenue grew 13100% from FY2021 to FY2025.
- Trading 22% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review GERON CORP.
Write a review
News about GERON CORP
News & sentiment via Polygon.io
Geron Corp: frequently asked questions
Is Geron Corp an American company?
Geron Corp is a US-based company headquartered in Foster City, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Geron Corp headquartered?
Geron Corp is headquartered in Foster City, California, United States.
Is Geron Corp publicly traded?
Yes — Geron Corp is a publicly traded company. Its stock trades under the ticker symbol GERN on the NASDAQ.
What does Geron Corp do?
Geron Corp is an American Pharmaceuticals company in the Health & Beauty sector.
When was Geron Corp founded?
Geron Corp was founded in 1990.
